Evidence map›Paper›PMID 18679417›Full record

ArticleOncogene2008

Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.

Y-M Chang, L Bai, S Liu, J C Yang, H-J Kung, C P Evans

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 185 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Artemisinin liposomes regulates breast cancer metastasis and apoptosis through TIGIT/CD155 signal axis.Apoptosis : an international journal on programmed cell death · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Dual Drug Repurposing: The Example of Saracatinib.International journal of molecular sciences · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. microRNA-205 in prostate cancer: Overview to clinical translation.Biochimica et biophysica acta. Reviews on cancer · 2022
    Review
  18. Article
  19. Article
  20. Review

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Y-M ChangDepartment of Urology, University of California at Davis, Sacramento, CA 95817, USA.
L Bai
S Liu
J C Yang
H-J Kung
C P Evans
University of California, Davis · US

Funding

TYROSINE KINASES AND PROSTATE GROWTHR01DK052659 · NIDDK · UNIVERSITY OF CALIFORNIA DAVIS · PI KUNG, HSING-JIEN · 1997 to 2011
$2.9M
Androgen signaling and kinase regulation in PCAR01CA114575 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KUNG, HSING-JIEN · 2005 to 2009
$1.3M
Modeling androgen receptor in prostate cellsR01DK078243 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KUNG, HSING-JIEN · 2007 to 2010
$1.2M
Neurotrophins and Tyrosine Kinases in Prostate CancerK08DK060748 · NIDDK · UNIVERSITY OF CALIFORNIA DAVIS · PI EVANS, CHRISTOPHER P · 2002 to 2006
$609k
NCI NIH HHS R01 CA114575NIDDK NIH HHS K08 DK060748NIDDK NIH HHS K08 DK60748-01NIDDK NIH HHS R01 DK052659NIDDK NIH HHS R01 DK078243NIDDK NIH HHS R01 DK52659
6 · The paper itself

Abstract

Prostate cancer is the most frequently diagnosed cancer in American men. We have previously demonstrated that Src mediates androgen-independent proliferation in prostate cancer. We sought to investigate the Src-mediated oncogenic pathways and tumor biology using AZD0530, a novel Src family kinase/Abl dual-kinase inhibitor that is entering phase II clinical trials. We show that while both Src and Abl are expressed in all prostate cancer cell lines, Src but not Abl is activated in the prostate. Furthermore, Src activation is inhibited by AZD0530 in a rapid and dose-dependent manner. We show that Src mediates cell proliferation in DU145 and PC3 cells at the G1 phase of cell cycle. Src inhibition resulted in decreased binding of beta-catenin to the promoters of G1 phase cell cycle regulators cyclin D1 and c-Myc. C-Myc may also be regulated at the protein level by extracellular signal-regulated kinase 1/2 and GSK3beta. Cell motility factors focal adhesion kinase, p130CAS and paxillin activation in DU145 and PC3 cells were also inhibited. Administration of AZD0530 in mice reduced orthotopic DU145 xenograft growth by 45%. We have further delineated the Src-mediated oncogenic growth and migration pathways in prostate cancer and established mechanistic rationale for Src inhibition as novel therapy in the treatment of prostate cancer.

Indexed as

Antineoplastic AgentsBenzodioxolesbeta CateninCell CycleCell Line, TumorCell MovementCell ProliferationCrk-Associated Substrate ProteinCyclin DCyclinsDose-Response Relationship, DrugEnzyme ActivationExtracellular Signal-Regulated MAP KinasesFocal Adhesion Protein-Tyrosine KinasesGene Expression Regulation, NeoplasticHumansAntineoplastic AgentsBCAR1 protein, humanBenzodioxolesbeta CateninCrk-Associated Substrate ProteinCyclin DCyclinsExtracellular Signal-Regulated MAP KinasesFocal Adhesion Protein-Tyrosine KinasesGSKIP protein, humanProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mycQuinazolinesRepressor Proteinssaracatinibsrc-Family Kinases

Identifiers

PMID18679417
PMCPMC4294546
OpenAlexW1989901669

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.